CooperVision to Launch of MyDay MiSight 1 Day Contact Lenses in Europe
CooperVision announced the upcoming launch of MyDay MiSight 1 day contact lenses in the UK and select European and surrounding markets.
The new daily disposable soft contact lens combines MiSight 1 day ActivControl Technology, which CooperVision says is supported by clinical evidence for slowing the progression of myopia in children, with the advanced silicone hydrogel material used in CooperVision’s MyDay lenses.1 This integration is designed to deliver effective myopia control while maintaining the comfort, breathability, and eye health benefits associated with silicone hydrogel daily wear.
MyDay MiSight 1 day builds on the success of MiSight 1 day, the first soft contact lens approved in several markets for myopia control in children, by incorporating a material platform known for high oxygen transmissibility and all-day comfort. The combination aims to support long-term eye health while meeting the practical needs of young, active wearers.
“The forthcoming launch of MyDay MiSight 1 day reflects our ongoing commitment to innovation in myopia management,” CooperVision said. “As the prevalence of myopia continues to rise across Europe, eye care professionals are seeking proven, science-led solutions. This new lens brings together trusted myopia control technology with an advanced daily disposable material to help address that need.”
The rollout will begin in the UK, followed by availability in select European and surrounding markets as regulatory approvals are completed. CooperVision said it expects the launch to further strengthen its position as a global leader in myopia management by offering a broader range of clinically supported options for children and their families.
CooperVision today announced the forthcoming launch of MyDay MiSight 1 day contact lenses in the UK and select European and surrounding markets, marking an expansion of the company’s evidence-based myopia management portfolio.
The new daily disposable soft contact lens combines MiSight 1 day ActivControl Technology, which is supported by strong clinical evidence for slowing the progression of myopia in children, with the advanced silicone hydrogel material used in CooperVision’s MyDay lenses. This integration is designed to deliver effective myopia control while maintaining the comfort, breathability, and eye health benefits associated with silicone hydrogel daily wear.
MyDay MiSight 1 day builds on the success of MiSight 1 day, the first soft contact lens approved in several markets for myopia control in children, by incorporating a material platform known for high oxygen transmissibility and all-day comfort. The combination aims to support long-term eye health while meeting the practical needs of young, active wearers.
“The forthcoming launch of MyDay MiSight 1 day reflects our ongoing commitment to innovation in myopia management,” CooperVision said. “As the prevalence of myopia continues to rise across Europe, eye care professionals are seeking proven, science-led solutions. This new lens brings together trusted myopia control technology with an advanced daily disposable material to help address that need.”
The rollout will begin in the UK, followed by availability in select European and surrounding markets as regulatory approvals are completed. CooperVision expects the launch to further strengthen its position as a global leader in myopia management by offering a broader range of clinically supported options for children and their families.
Reference
- Based on CooperVision data on file and published clinical evidence supporting MiSight 1 day ActivControl Technology and MyDay silicone hydrogel material.
Originally published online on Eyewire+.